Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388882 · ClinicalTrials.gov registry record · Phase 4
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT00388882: Completed Phase 4 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
NCT00388882 is a Phase 4 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 327 participants, below the 1,040-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388882, a Phase 4 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.
Conditions Studied
Interventions
- DRUG tiotropium
- DRUG ipratropium bromide / albuterol
Study Locations (20)
Other
- 205.346.510 - Bs As
- 205.346.502 - Buenos Aires
- 205.346.503 - Buenos Aires
- 205.346.508 - Buenos Airess
- 205.346.505 - Mendoza
- 205.346.509 - Rosario, Santa Fe
- 205.346.511 - Rosario, Santa Fé
- 205.346.504 Instituto de Patologías Respiratorias - San Miguel de Tucumán
- 205.346.401 Boehringer Ingelheim Investigational Site - Alytus
- 205.346.404 Boehringer Ingelheim Investigational Site - Kaunas
California
- 205.346.104 Boehringer Ingelheim Investigational Site - Lakewood
- 205.346.108 Boehringer Ingelheim Investigational Site - Sepulveda
- 205.346.101 Boehringer Ingelheim Investigational Site - Torrance
South Carolina
- 205.346.105 Boehringer Ingelheim Investigational Site - Charleston
- 205.346.103 Boehringer Ingelheim Investigational Site - Spartanburg
Arizona
- 205.346.107 Boehringer Ingelheim Investigational Site - Phoenix
Colorado
- 205.346.106 Boehringer Ingelheim Investigational Site - Wheat Ridge
Idaho
- 205.346.102 Boehringer Ingelheim Investigational Site - Coeur d'Alene
Louisiana
- 205.346.109 Boehringer Ingelheim Investigational Site - Shreveport
Pennsylvania
- 205.346.110 Boehringer Ingelheim Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2006-10-04 |
| Phase | Phase 4 |
What the finished NCT00388882 record still lists
NCT00388882 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, below the 1,040-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which tiotropium is the first listed.
NCT00388882 names 20 study sites across 8 states, led by Other, California, South Carolina.
Frequently Asked Questions
What is clinical trial NCT00388882 about?
NCT00388882 is a clinical study titled "Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.". The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.
What is the current status of trial NCT00388882?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 327 participants. The study started on 2006-10-04.
What conditions does trial NCT00388882 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00388882?
The interventions under investigation include: tiotropium (DRUG), ipratropium bromide / albuterol (DRUG).
Who is sponsoring clinical trial NCT00388882?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00388882 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00388882's enrollment target sits among peer trials
327 34th of 74 higher than 41 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
COMPLETED · Phase 4
-
Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD
COMPLETED · Phase 4
-
Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)
COMPLETED · Phase 4
-
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
COMPLETED · Phase 4
-
Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects
COMPLETED · Phase 4
-
Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI